Clinical Trial

Mirdametinib in Histiocytic Disorders

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if treatment with mirdametinib in patients with Langerhans cell histiocytosis (LCH) or other histiocytic disorders will be better than current treatments and with fewer side effects.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-11-22; most recent amendment 2025-09-10.
Status change: Not Yet Recruiting → Recruiting 2023-12-06
Trial Details
NCT Number NCT06153173
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Conditions Langerhans Cell Histiocytosis (LCH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman Disease (RDD), Histiocytic Disorders
Enrollment 40 participants
Start Date 2024-02-05
Primary Completion 2030-03 (estimated)
Study Completion 2031-03 (estimated)
Updated on ClinicalTrials.gov 2025-09-16